-
Healthcare Professionals-Perceived Benefits and Opportunities to Improve an Electronic Patient-Reported Outcomes (ePRO)-Based Remote Symptom Monitoring (RSM) Program During Cancer Treatment
Sep 9, 2025, 16:22 PM -
Evaluating Therapeutic Landscape in Radio-Iodine-Refractory–Differentiated Thyroid Cancer (DTC): A Bayesian Network Meta-Analysis of Clinical Efficacy
Sep 9, 2025, 16:22 PM -
Real-World Evidence on Healthcare Resource Utilization (HCRU) and Economic Burden of Patients With COPD Treated With Dual or Triple Therapy: Stratified Analysis by Blood Eosinophil Count and Exacerbation Phenotype in the BREATHE-IN Study
Sep 9, 2025, 16:22 PM -
Costs Associated With the Treatment of Surgical Site Infections in Solid Organ Transplant Recipients: A Scoping Review
Sep 9, 2025, 16:22 PM -
From Workshops to a Dashboard Prototype: Evaluating a Checklist Approach and User Design for Digital Health Technology Assessment
Sep 9, 2025, 16:22 PM -
Exploring the Broader Value of Adult Respiratory Vaccination Programs in Greece: A Public Health Perspective
Sep 9, 2025, 16:22 PM -
Clinical Profile of Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Treated With Complement Inhibitors: Results From a Real-World Study
Sep 9, 2025, 16:22 PM -
Application and Future Potential of Generative Artificial Intelligence (Gen AI) And Large Language Model (LLM) In Health Economics and Outcomes Research (HEOR)
Sep 9, 2025, 16:22 PM -
Predicting the Maximum Fair Price (MFP) From Medicare Negotiations
Sep 9, 2025, 16:22 PM -
Budget Impact Analysis of Eplerenone For the Management of Heart Failure With Reduced Ejection Fraction (HFrEF) in Italy
Sep 9, 2025, 16:22 PM -
Characterizing Exploratory Endpoints in Early Oncology Trials: Insights From Trial Registry Audit
Sep 9, 2025, 16:22 PM -
Navigating the MFN Pricing Era: Strategic Imperatives for Biopharma
Sep 9, 2025, 16:22 PM -
Comprehensive Landscape Assessment of Real-World Databases for HEOR Studies in the Asia-Pacific Region: A Growing Opportunity
Sep 9, 2025, 16:22 PM -
Cost-Effectiveness Analysis of Gemcitabine Nabpaclitaxel Combination, Modified FOLFIRINOX, and SIROX As First-Line Therapy for Pancreatic Cancer
Sep 9, 2025, 16:22 PM -
Risk, Time in Hospital, and Associated Costs? of Hospitalizations in Individuals With Infantile-Onset SMA: Results From DEVOTE Part B
Sep 9, 2025, 16:22 PM -
Resilient Pharmaceutical Supply Chains in Times of Crisis: A Comparative Analysis of Australia, France, Italy, Spain, and UK
Sep 9, 2025, 16:22 PM -
Cost-Effectiveness Assessment of 20-Valent Pneumococcal Conjugate Vaccine (PCV20) Among At-Risk and High-Risk Adults in India
Sep 9, 2025, 16:22 PM -
Real-World Insights Into Breast Cancer in the UK: Findings From UK EHR-Derived Data
Sep 9, 2025, 16:22 PM -
Analysis of the Epidemiological Disease Burden of Endometriosis in Hungary Based on Data From the Global Burden of Disease Study
Sep 9, 2025, 16:22 PM -
From Theory to Practice: Guidance for Identifying and Selecting Mapping Algorithms for Health Economic Models
Sep 9, 2025, 16:22 PM
